Krynetskaia NF, Xie M, Vucetic S., Obradovic Z, Krynetskiy EY. High mobility group protein B1 is an activator of apoptotic response to the chemotherapeutic agents 5-fluorouracil, cytosine arabinoside, and mercaptopurine. Mol. Pharmacology, 2007 Oct 19; [Epub ahead of print]
PMID: 17951356.

Krynetskiy E. and McDonnell P. Building Individualized Medicine: Prevention of Adverse Reactions to Warfarin Therapy. Journal of Pharmacology and Experimental Therapeutics (invited review) 322 (2):427-434 (2007).

Nasedkina TV_, Fedorova OE, Glotov AS, Chupova NV, Samochatova EV, Maiorova OA, Zemlyakova VV, Roudneva AE, Chudinov AV, Yurasov RA, Kozhekbaeva JM, Barsky VE, Krynetskiy EY, Krynetskaia NF, Cheng C, Ribeiro RC, Evans WE, Roumyantsev AS, Zasedatelev AS.^. Rapid genotyping of common deficient thiopurine S-methyltransferase (TPMT) alleles using the DNA-microchip technique. Eur J Hum Genet. 14: 991-998 (2006).

Brown VM, Krynetski EY, Krynetskaia NF, Grieger D, Mukatira ST, Murti KG, Slaughter CA, Park H-W, Evans WE. A Novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. J Biol Chem 279(7): 5984-5992, 2004.

Krynetski EY, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22, 7403-7413, 2003.

Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 63(1):100-106, 2003.

Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW.  Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 278(2): 1005-1011, 2003.

 McDonald OG, Krynetski EY, Evans WE. Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics 12: 3-99, 2002.

Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE.  A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol 59(2): 367-374, 2001.

Krynetskaia NF, Feng JY, Krynetski EY, Garcia JV, Panetta JC, Anderson KS, Evans WE. Deoxythioguanosine triphosphate impairs HIV replication: A new mechanism for an old drug.  FASEB J 15:1902-1908, 2001.

Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 14:2339-2344, 2000.

Krynetskaia NF, Krynetski EY. Elucidating the targets of antileukemic agents: Molecular mechanisms of mercaptopurine action. Mol Biol (Russian Academy of Science) 34(6): 1046-1053, 2000.

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999.

Krynetskaia NF, Krynetski EY, Evans WE. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 56:841-848, 1999.

Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE. Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93:1643-1650, 1999.

Fessing MY, Krynetski EY, Zambetti GP, Evans WE. Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur J Biochem 256:510-517, 1998.

Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614, 1997.

Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94:6444-6449, 1997.

Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 47:1141-1147, 1995.

Krynetski EY, Schuetz JD, Galpin AJ, Pui PH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92:949-953, 1995.

Krynetski EY, Drutsa VL, Kovaleva IE, Luzikov VN. High yield expression of functionally active human liver CYP2D6 in yeast cells. Pharmacogenetics 5:103-109, 1995.

Krynetski EY, Kovaleva IE, Luzikov VN. Heterologous expression of functional human cytochromes P450.III. Cytochrome P450IIIA4 catalyzes biotransformation of an anabolic steroidal drug methandrostenolone. Biokhimia (Russ) 59:282-286, 1994.

Krynetski E, Kovaleva IE. Evaluation of the transcription of the human cytochrome P450IID6-encoding gene by PCR. Mol Biol (Russ) 26:943-948, 1992.

Krynetski EY, Maruzhenkov DS, Prokhorov BS, Krylov YF. Metabolism of synthetic glucocorticoidal drugs prednisolone and dexamethasone in rats and in in vitro reactions. Exp Clin Pharmacol (Russ) 55:51-53, 1992.

Krynetski EY, Maruzhenkov DS, Prokhorov BS, Rylin AF. Imprinting of steroidal metabolism caused by an anabolic drug methandrostenolone. Problems of Endocrynology (Russ) 37:45-47, 1991.

Krynetski EY, Maruzhenkov DS, Prokhorov BS, Rylin AF. Structure of methandrostenolone metabolites formed in rats. Pharmacol Toxicol (Russ) 53:51-53, 1990.

Krynetski EY, Ivanovskaia MG, Drutsa VL, Purmal AA, Sokolova NI, Shabarova ZA. Synthesis of a photoaffinity derivative of the octadeoxyribonucleotide complementary to the 3'-terminal fragment of 16S rRNA of E.coli. Proc Acad Sci USSR (Russ) 247:752-754, 1979.